Restoring metabolic balance

Harnessing precision-targeted drug delivery technology for the treatment and prevention of metabolic disorders such as obesity and related diseases

Our Approach

Metabolic Diseases: A Global Epidemic

Metabolic disorders such as obesity or type 2 diabetes have presented as a health and economic problem of global proportions over the past 40 years. Perturbations of the endocrine balance are a hallmark of most of these disorders. Safely restoring metabolic balance is the key to treating and preventing them.

LEARN MORE

APH-012

We believe that our lead candidate, APH-012, has the potential to revolutionize the treatment of metabolic diseases like obesity and type 2 diabetes. APH-012 uniquely induces the release of the full spectrum of enteral hormones that control appetite, hunger, satiety, glucose metabolism, and other homeostatic functions.

LEARN MORE

Programs

Phase 2 Trial in Obesity

APH-012 is being evaluated in a Phase 2 proof-of-concept study in individuals with obesity The trial will evaluate APH-012’s ability to change individual’s percent weight compared to placebo, in addition to other key parameters which are hallmarks of multiple metabolic diseases closely associated with obesity.

LEARN MORE